Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ-LARC2 Vaccine in Malaria-naïve Adults
NCT06862453Phase 1Recruiting
- Sponsor
- Sanaria Inc.
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PfSPZ-LARC2 in malaria (8 cohorts), sponsored by Sanaria Inc. Primary endpoints: Safety and tolerability of administration of PfSPZ-LARC2 Vaccine: infection, Safety and tolerability of administration of PfSPZ-LARC2 Vaccine: related AEs and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
PfSPZ-LARC2
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06862453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06862453.